Rabies Trick Could Help Treat Parkinson's Disease
News Apr 26, 2018 | Original Story from the American Chemical Society.
The rabies virus wreaks havoc on the brain, triggering psychosis and death. To get where it needs to go, the virus must first trick the nervous system and cross the blood brain barrier — a process that makes it of interest in drug design. Now, scientists report in ACS Nano a way to exploit the rabies virus machinery to deliver a Parkinson's disease medication directly to the brain.
Parkinson's disease, the slow degeneration of the brain cells that control movement, affects about a million Americans, according to the Parkinson's Foundation, and has no cure. While the exact cause of Parkinson's disease is unknown, a common feature of the illness is the accumulation of iron in neurons, inflicting damage and cell death. Some doctors are now using a metal-grabbing compound called deferoxamine to sop up the excess iron in patients, but high doses are needed due to the drug's limited capacity to enter the brain, bringing on serious side effects. To lower the effective dose, Yan-Zhong Chang, Xin Lou, Guangjun Nie, and colleagues wanted to take advantage of a key part of the rabies virus to usher deferoxamine into the brain.
Glycoprotein 29 is a part of the rabies virus that binds to a brain cell receptor and crosses the blood brain barrier. The researchers attached glycoprotein 29 to a nanoparticle stuffed full of deferoxamine. Then, they injected the iron-grabbing nanoparticles into mouse models of Parkinson's disease. The iron levels in the mouse brains dropped, reducing the brain damage and reversing the disease symptoms, without noticeable side effects. Since all of the components in the therapeutic agent are already approved for use in the clinic, the researchers are looking toward human trials.
This article has been republished from materials provided by the American Chemical Society. Note: material may have been edited for length and content. For further information, please contact the cited source.
Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice. Linhao You, Jing Wang, Tianqing Liu, Yinlong Zhang, Xuexiang Han, Ting Wang, Shanshan Guo, Tianyu Dong, Junchao Xu, Gregory J. Anderson, Qiang Liu, Yan-Zhong Chang, Xin Lou, and Guangjun Nie. ACS Nano, DOI: 10.1021/acsnano.7b08172.
Researchers who sequenced the fecal samples of over 3,000 healthy volunteers recently described the so-called B2 enterotype, which is deficient in some anti-inflammatory bacteria. Today, they published more data, showing the high prevalence of this particular enterotype across multiple disease diagnoses.READ MORE